Research Analysts Offer Predictions for CMPX FY2028 Earnings

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Investment analysts at HC Wainwright raised their FY2028 earnings per share estimates for Compass Therapeutics in a report released on Tuesday, November 12th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of $0.94 per share for the year, up from their previous forecast of $0.85. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.42) per share.

Several other research analysts have also recently commented on CMPX. Wedbush reiterated an “outperform” rating and issued a $8.00 target price on shares of Compass Therapeutics in a report on Wednesday, August 7th. LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price on the stock in a research report on Monday, September 16th.

Compass Therapeutics Trading Down 2.1 %

Shares of Compass Therapeutics stock traded down $0.04 on Thursday, reaching $1.66. 32,726 shares of the company were exchanged, compared to its average volume of 431,274. Compass Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $2.34. The firm has a market capitalization of $227.71 million, a price-to-earnings ratio of -4.57 and a beta of 0.92. The stock has a fifty day moving average price of $1.75 and a 200-day moving average price of $1.42.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03.

Institutional Trading of Compass Therapeutics

Several hedge funds have recently modified their holdings of the company. Rovin Capital UT ADV acquired a new position in Compass Therapeutics in the third quarter valued at approximately $25,000. Intech Investment Management LLC bought a new position in Compass Therapeutics in the third quarter valued at $30,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Compass Therapeutics in the 2nd quarter valued at approximately $41,000. Panagora Asset Management Inc. acquired a new position in Compass Therapeutics during the second quarter worth approximately $68,000. Finally, SG Americas Securities LLC boosted its holdings in shares of Compass Therapeutics by 16.6% during the 3rd quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock worth $71,000 after buying an additional 5,515 shares during the period. Institutional investors and hedge funds own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.